Cargando…

Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation

PPARγ is the functioning receptor for the thiazolidinedione (TZD) class of anti-diabetes drugs including rosiglitazone and pioglitazone(1). These drugs are full classical agonists for this nuclear receptor, but recent data has shown that many PPARγ-based drugs have a separate biochemical activity, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jang Hyun, Banks, Alexander S., Kamenecka, Theodore M., Busby, Scott A., Chalmers, Michael J., Kumar, Naresh, Kuruvilla, Dana S., Shin, Youseung, He, Yuanjun, Bruning, John B., Marciano, David P., Cameron, Michael D., Laznik, Dina, Jurczak, Michael J., Schürer, Stephan C., Vidović, Dušica, Shulman, Gerald I., Spiegelman, Bruce M., Griffin, Patrick R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179551/
https://www.ncbi.nlm.nih.gov/pubmed/21892191
http://dx.doi.org/10.1038/nature10383
Descripción
Sumario:PPARγ is the functioning receptor for the thiazolidinedione (TZD) class of anti-diabetes drugs including rosiglitazone and pioglitazone(1). These drugs are full classical agonists for this nuclear receptor, but recent data has shown that many PPARγ-based drugs have a separate biochemical activity, blocking the obesity-linked phosphorylation of PPARγ by Cdk5(2). Here we describe novel synthetic compounds that have a unique mode of binding to PPARγ, completely lack classical transcriptional agonism and block the Cdk5-mediated phosphorylation in cultured adipocytes and in insulin-resistant mice. Moreover, one such compound, SR1664, has potent anti-diabetic activity while not causing the fluid retention and weight gain that are serious side effects of many of the PPARγ drugs. Unlike TZDs, SR1664 also does not interfere with bone formation in culture. These data illustrate that new classes of anti-diabetes drugs can be developed by specifically targeting the Cdk5-mediated phosphorylation of PPARγ.